Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states
- Written by PR Newswire Asia - News Pronto RSS
 |
Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants
SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and...